Oncology Daily Report: 01/27/2024
Breast Cancer (Advanced)
A randomized phase 3 trial investigated the effect of veliparib with carboplatin and paclitaxel in 509 patients with BRCA1/2-mutated, HER2-negative advanced breast cancer and found median OS was 32.4 months with veliparib vs 28.2 months with placebo (hazard ratio, 0.916; 95% CI, 0.736-1.140; P = .434) (1). The PFS improvement did not translate into an OS benefit, but long survival times suggest that combination therapy provides clinical benefit in this population.
Reference
Diéras V, Han HS, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Loirat D, Ratajczak C, Adamu H, Girardi V, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024 Jan 28;200:113580. doi: 10.1016/j.ejca.2024.113580. Epub ahead of print. PMID: 38309017.
Gastric or Gastroesophageal Junction Cancer (Advanced/Metastatic)
An international, randomized, placebo-controlled, phase 3 trial investigated the effect of rivoceranib in 460 patients with advanced or metastatic gastric or gastroesophageal junction cancer who had failed ≥2 lines of chemotherapy and found no significant difference in median OS (5.78 months with rivoceranib vs. 5.13 months with placebo; hazard ratio [HR] 0.93, 95% CI 0.74-1.15; p = 0.4724) (1). However, rivoceranib improved PFS (median 2.83 vs. 1.77 months; HR 0.58, 95% CI 0.47-0.71; p < 0.0001), ORR (6.5% vs. 1.3%; p = 0.0119), and DCR (40.3 vs. 13.2%; p < 0.0001) compared to placebo. In patients receiving ≥4th-line therapy, rivoceranib improved OS (median 6.34 vs. 4.73 months; p = 0.0192) and PFS.
Reference
Kang YK, Ryu MH, Di Bartolomeo M, Chau I, Yoon H, Kim JG, Lee KW, Oh SC, Takashima A, Kryzhanivska A, Chao Y, Evesque L, Schenker M, McGinn A, Zhao Y, Lee J, Wyrwicz L, Boku N. Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial. Gastric Cancer. 2024 Jan 28. doi: 10.1007/s10120-023-01455-5. Epub ahead of print. PMID: 38281295.